



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 10.02.2021

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor
Plot No.62, G-Block, Opp Trident Hotel,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 098

Dear Sir,

Sub: outcome of the Board Meeting held today i.e., on 10th February, 2021 -- Reg.

We wish to inform you that the Board of Directors at its Meeting held today i.e., on 10th February, 2021 has inter-alia, transacted the following items of business:.

1. Approved the Un-Audited financial Results, for the quarter and nine months ended 31st December, 2020, as recommended by the audit committee.
2. Took note of the Limited Review Report on Un-Audited Financial statements for the quarter and nine months ended 31st December, 2020.
3. Appointed Mrs. Shilpa Bung (DIN: 08257931) as an Additional Director (Independent Women Director) of the company.
4. Miss. K. Suneetha (DIN: 03291895) has attended today's Board meeting held on 10-2-2021 and submitted her resignation letter and Board took note of the same.

We herewith enclose the following:

- A. Un-Audited financial Results for the quarter and nine months ended 31st December, 2020.
- B. Limited Review Report issued by statutory auditors of the company.
- C. Brief profile of Mrs. Shilpa Bung (DIN: 08257931), who is appointed as an Additional Director (Independent Women Director) of the company.
- D. Copy of Resignation letter of Miss. K. Suneetha (DIN: 03291895) as a Director of the company.

This is for your information and necessary records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited



B. Kumar
(Boina Kumar)

Chief Financial Officer

Meeting Commenced at 4:00 P.M.
Meeting Concluded at 5:10 P.M.

SIGACHI LABORATORIES LIMITED

Regd Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Un-Audited Financial Results For The Quarter and Nine Months Ended 31st December, 2020

Digitally signed
by T
RAJASEKHAR
Date:
2021.02.10
17:10:32 +05'30'

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Nine Months Ended		Year ended 31.03.2020
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	
1	Revenue from operations	113.78	70.90	54.60	269.29	111.56	66.51
2	Other income	9.36	11.86	25.77	22.76	93.58	106.07
3	Total Income (1+2)	123.14	82.76	80.37	292.05	205.14	172.58
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-	-
	d) Employee benefits expense	6.83	7.24	5.87	19.37	21.07	27.99
	e) Finance costs	-	-	-	-	-	-
	f) Depreciation and amortization expense	4.15	4.14	4.14	12.43	11.27	15.32
	g) Other expenses	2.03	2.15	2.23	6.86	9.18	12.64
	Total Expenses	13.01	13.53	12.24	38.66	41.52	55.96
5	Profit/(loss) before exceptional and extraordinary items and tax (3-4)	110.13	69.23	68.13	253.39	163.62	116.62
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(loss) before extraordinary items and tax (5-6)	110.13	69.23	68.13	253.39	163.62	116.62
8	Extraordinary items	-	-	-	-	-	-
9	Profit/(Loss) before tax (7-8)	110.13	69.23	68.13	253.39	163.62	116.62
10	Tax expense						
	(a) Current tax	9.92	10.66	12.00	26.33	24.00	44.03
	(b) Deferred tax	0.01	(1.85)	1.44	(1.64)	1.71	1.94
	Total Tax Expense	9.93	8.81	13.44	24.69	25.71	45.97
11	Profit/(Loss) for the Period (9-10)	100.20	60.42	54.69	228.70	137.91	70.65
12	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or loss	170.36	55.07	26.94	383.75	0.97	(226.96)
	(b) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	170.36	55.07	26.94	383.75	0.97	(226.96)
	Total Comprehensive income (11+12)	270.56	115.49	81.63	612.45	138.88	(156.31)
13	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31
14	Other Equity	-	-	-	-	-	1,256.34
15	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))						
	(1) Basic	1.48	0.89	0.81	3.39	2.04	1.05
	(2) Diluted	1.48	0.89	0.81	3.39	2.04	1.05

Segment wise Revenue, Results and Capital Employed for the Quarter & Nine Months Ended 31st December, 2020

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Nine Months Ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	29.00	28.50	27.50	76.50	72.50	110.50
	b) Investments	94.14	54.26	52.87	215.55	132.64	62.08
	Total	123.14	82.76	80.37	292.05	205.14	172.58
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net sales/Income from Operations	123.14	82.76	80.37	292.05	205.14	172.58
2	Segment Results Profit/ (Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	24.69	24.20	23.21	63.22	60.15	93.55
	b) Investments	94.14	54.26	52.87	215.55	132.64	62.07
	Total	118.83	78.46	76.08	278.77	192.79	155.62
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	8.70	9.23	7.95	25.38	29.17	39.00
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	110.13	69.23	68.13	253.39	163.62	116.62
3	Capital Employed						
	(Segment assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	618.40	601.43	568.68	618.40	568.68	576.05
	b) Investments	1,981.44	1,727.85	1,713.88	1,981.44	1,713.88	1,411.34
	Total	2,599.84	2,329.28	2,282.56	2,599.84	2,282.56	1,987.39

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 10th February, 2021.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The outbreak of COVID-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a significant decrease in the economic activities. On 11th March, 2020, the COVID-19 outbreak was declared as a global pandemic by the World Health Organisation. On 24th March, 2020, the Indian Government had announced a strict 21 day lockdown which kept on getting extended across the country with gradual and modest relaxations. Given the dynamic nature of the pandemic situation, the carrying value of the Company's investments and loans as at December 31, 2020, may be affected by the severity and duration of the outbreak, however the Company believes that it has taken into account all the possible impact of known events arising out of COVID 19 pandemic in the preparation of financial results resulting out of fair valuation of these investments. However the impact assessment of COVID 19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes to future economic conditions.
- Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board
for SIGACHI LABORATORIES LIMITED

T
RAJASEKHAR
Date: 2021.02.10
17:11:26 + 05:30
(T.R.Sekhar)
Executive Director
DIN:02943146

Place : Hyderabad
Date : 10.02.2021

INDEPENDENT AUDITORS' REVIEW REPORT

To
The Board of Directors,
Sigachi Laboratories Limited,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sigachi Laboratories Limited** ("the company") for the quarter ended 31st December, 2020 and year to date results for the period from 1st April, 2020 to 31st December, 2020, ("the statement") being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind As 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 10.02.2021

Place : Hyderabad



For Niranjana & Narayan
Chartered Accountants
FRN: 005899S

A handwritten signature in blue ink, appearing to read "M. Niranjana".

M. Niranjana

Partner - Memb. No. 029552

UDIN: 21029552AAAAABQ7198